Related Experiment Videos

[Pharmacokinetics and clinical studies of flomoxef in the pediatric field]

T Motohiro1, K Oda, M Aramaki

  • 1Department of Pediatrics, School of Medicine, Kurume University.

Insights

This study evaluated Flomoxef (FMOX), a new intravenous cephem antibiotic, in pediatric patients. Results show a dose-dependent relationship in plasma and urine concentrations, indicating FMOX

Area of Science:

  • Pharmacology and Therapeutics
  • Infectious Diseases
  • Pediatric Medicine

Context:

  • Flomoxef (FMOX) is a novel intravenous cephem antibiotic.
  • The study focused on pediatric patients aged 7 to 10 years.
  • Evaluated administration via single intravenous injection and 30-minute intravenous drip infusion.

Purpose:

  • To determine the pharmacokinetic profile of Flomoxef (FMOX) in pediatric patients.
  • To assess the clinical efficacy and safety of FMOX in treating various infections.
  • To investigate dose-response relationships for plasma and urine concentrations.

Summary:

  • Pharmacokinetic parameters including peak plasma concentrations, half-life, and AUC were determined for different FMOX doses (10, 20, 40 mg/kg).
  • A positive dose-response relationship was observed for both plasma and urine concentrations.
  • Clinical efficacy was evaluated in 60 pediatric cases with infections like pneumonia and urinary tract infections.

Impact:

  • Provides crucial pharmacokinetic and efficacy data for Flomoxef (FMOX) in pediatric populations.
  • Supports the use of FMOX as an effective intravenous antibiotic option for pediatric infections.
  • Highlights the importance of dose selection for achieving optimal therapeutic concentrations.

Related Concept Videos